{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:41:49Z","timestamp":1792597309447,"version":"4.5.0"},"reference-count":168,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010950","name":"Department of Science and Technology of Henan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018925","name":"Henan Province Health and Family Planning Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Henan Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bbcan.2024.189186","type":"journal-article","created":{"date-parts":[[2024,9,25]],"date-time":"2024-09-25T06:39:23Z","timestamp":1727246363000},"page":"189186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combination therapies with Wnt signaling inhibition: A better choice for prostate cancer treatment"],"prefix":"10.1016","volume":"1879","author":[{"given":"Yifan","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changsheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0005","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41572-021-00249-2","volume":"7","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bbcan.2024.189186_bb0010","article-title":"Burden of prostate cancer in China, 1990-2019: findings from the 2019 global burden of disease study","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0015","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.euo.2021.09.006","article-title":"Epidemiology and prevention of prostate cancer","volume":"4","author":"Gandaglia","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.bbcan.2024.189186_bb0020","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0025","doi-asserted-by":"crossref","first-page":"2279235","DOI":"10.1080\/07853890.2023.2279235","article-title":"Molecular classifications of prostate cancer: basis for individualized risk stratification and precision therapy","volume":"55","author":"Ge","year":"2023","journal-title":"Ann. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","article-title":"Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer from the PREVAIL trial","volume":"78","author":"Armstrong","year":"2020","journal-title":"Eur. Urol."},{"issue":"22","key":"10.1016\/j.bbcan.2024.189186_bb0035","article-title":"What do we have to know about PD-L1 expression in prostate cancer? A systematic literature review. Part 3: PD-L1, intracellular signaling pathways and tumor microenvironment","volume":"22","author":"Palicelli","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.bbcan.2024.189186_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3835(02)00413-5","article-title":"The role of androgens and the androgen receptor in prostate cancer","volume":"187","author":"Debes","year":"2002","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2024.189186_bb0045","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","article-title":"A new old target: androgen receptor signaling and advanced prostate cancer","volume":"62","author":"Westaby","year":"2022","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189186_bb0050","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrurol.2017.144","article-title":"WNT signalling in prostate cancer","volume":"14","author":"Murillo-Garz\u00f3n","year":"2017","journal-title":"Nat. Rev. Urol."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189186_bb0055","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Watson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ajur.2019.11.001","article-title":"Posttranslational regulation of androgen dependent and independent androgen receptor activities in prostate cancer","volume":"7","author":"Wen","year":"2020","journal-title":"Asian J. Urol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0065","first-page":"803","article-title":"Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays","volume":"59","author":"Bubendorf","year":"1999","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189186_bb0070","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/nm.4070","article-title":"ROR-\u03b3 drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer","volume":"22","author":"Wang","year":"2016","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189186_bb0075","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","article-title":"Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity","volume":"63","author":"Beltran","year":"2013","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0080","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0006-291X(05)80067-1","article-title":"A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens","volume":"173","author":"Veldscholte","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189186_bb0085","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/nrurol.2014.145","article-title":"Prostate cancer: an enzalutamide antiandrogen withdrawal syndrome","volume":"11","author":"Phillips","year":"2014","journal-title":"Nat. Rev. Urol."},{"issue":"7406","key":"10.1016\/j.bbcan.2024.189186_bb0090","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nature11125","article-title":"The mutational landscape of lethal castration-resistant prostate cancer","volume":"487","author":"Grasso","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bbcan.2024.189186_bb0095","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1172\/JCI41824","article-title":"Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant","volume":"120","author":"Sun","year":"2010","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0100","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/0008-5472.CAN-12-3630","article-title":"Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines","volume":"73","author":"Li","year":"2013","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019059","article-title":"Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival","volume":"6","author":"H\u00f6rnberg","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrurol.2014.320","article-title":"Targeting heat shock proteins in metastatic castration-resistant prostate cancer","volume":"12","author":"Azad","year":"2015","journal-title":"Nat. Rev. Urol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0115","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1677\/ERC-10-0059","article-title":"Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients","volume":"17","author":"Crnalic","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"issue":"5","key":"10.1016\/j.bbcan.2024.189186_bb0120","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0125","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0130","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1158\/1078-0432.CCR-13-1863","article-title":"Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer","volume":"20","author":"Yu","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0135","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ajpath.2021.11.007","article-title":"LRP5 promotes gastric cancer via activating canonical Wnt\/\u03b2-catenin and glycolysis pathways","volume":"192","author":"Nie","year":"2022","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0140","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/jcmm.17164","article-title":"LRP5 promotes cancer stem cell traits and chemoresistance in colorectal cancer","volume":"26","author":"Nie","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.bbcan.2024.189186_bb0145","doi-asserted-by":"crossref","first-page":"657","DOI":"10.3389\/fphar.2018.00657","article-title":"Interplay of miRNAs and canonical Wnt signaling pathway in hepatocellular carcinoma","volume":"9","author":"Nie","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bbcan.2024.189186_bb0150","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.3389\/fonc.2020.01341","article-title":"Emerging roles of Wnt ligands in human colorectal Cancer","volume":"10","author":"Nie","year":"2020","journal-title":"Front. Oncol."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189186_bb0155","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1158\/0008-5472.CAN-17-3006","article-title":"Inhibition of the Wnt\/\u03b2-catenin pathway overcomes resistance to enzalutamide in castration-resistant prostate Cancer","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0160","doi-asserted-by":"crossref","first-page":"36","DOI":"10.5534\/wjmh.2013.31.1.36","article-title":"Clinical significance of Wnt\/\u03b2-catenin signalling and androgen receptor expression in prostate CAN cer","volume":"31","author":"Jung","year":"2013","journal-title":"World J. Mens Health"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0165","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ccr.2013.01.002","article-title":"Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer","volume":"23","author":"Weischenfeldt","year":"2013","journal-title":"Cancer Cell"},{"issue":"16","key":"10.1016\/j.bbcan.2024.189186_bb0170","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1038\/s41388-020-1214-7","article-title":"Androgen receptor with short polyglutamine tract preferably enhances Wnt\/\u03b2-catenin-mediated prostatic tumorigenesis","volume":"39","author":"He","year":"2020","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0175","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/onc.2015.117","article-title":"Androgen signaling is a confounding factor for \u03b2-catenin-mediated prostate tumorigenesis","volume":"35","author":"Lee","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0180","doi-asserted-by":"crossref","first-page":"4364","DOI":"10.1038\/s41467-022-32119-0","article-title":"Aberrant androgen action in prostatic progenitor cells induces oncogenesis and tumor development through IGF1 and Wnt axes","volume":"13","author":"Kim","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0185","doi-asserted-by":"crossref","first-page":"6552","DOI":"10.1038\/s41467-022-34282-w","article-title":"Stromal androgen signaling acts as tumor niches to drive prostatic basal epithelial progenitor-initiated oncogenesis","volume":"13","author":"Hiroto","year":"2022","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0190","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41467-024-45489-4","article-title":"Androgen deprivation induces double-null prostate cancer via aberrant nuclear export and ribosomal biogenesis through HGF and Wnt activation","volume":"15","author":"Kim","year":"2024","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189186_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141589","article-title":"Divergent androgen receptor and beta-catenin signaling in prostate cancer cells","volume":"10","author":"Lee","year":"2015","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.bbcan.2024.189186_bb0200","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/1541-7786.MCR-12-0520","article-title":"Role of WNT7B-induced noncanonical pathway in advanced prostate cancer","volume":"11","author":"Zheng","year":"2013","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0205","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eururo.2013.08.011","article-title":"Next-generation sequencing of advanced prostate cancer treated with androgen-deprivation therapy","volume":"66","author":"Rajan","year":"2014","journal-title":"Eur. Urol."},{"issue":"41","key":"10.1016\/j.bbcan.2024.189186_bb0210","doi-asserted-by":"crossref","first-page":"17087","DOI":"10.1073\/pnas.1108745108","article-title":"Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers","volume":"108","author":"Kumar","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0215","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.dhjo.2017.12.002","article-title":"Disabilities moderate the association between neighbourhood urbanity and cognitive health: results from the Irish longitudinal study on ageing","volume":"11","author":"Cassarino","year":"2018","journal-title":"Disabil. Health J."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189186_bb0220","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.eururo.2021.12.039","article-title":"Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy","volume":"81","author":"Cheng","year":"2022","journal-title":"Eur. Urol."},{"issue":"15","key":"10.1016\/j.bbcan.2024.189186_bb0225","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1002\/pros.22868","article-title":"Activation of Wnt\/\u03b2-catenin signaling in a subpopulation of murine prostate luminal epithelial cells induces high grade prostate intraepithelial neoplasia","volume":"74","author":"Valkenburg","year":"2014","journal-title":"Prostate"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0230","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1158\/0008-5472.CAN-06-3028","article-title":"Inactivation of Apc in the mouse prostate causes prostate carcinoma","volume":"67","author":"Bruxvoort","year":"2007","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0235","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.ydbio.2008.01.030","article-title":"Sox9 is required for prostate development","volume":"316","author":"Thomsen","year":"2008","journal-title":"Dev. Biol."},{"issue":"Pt 1","key":"10.1016\/j.bbcan.2024.189186_bb0240","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.semcancer.2019.03.004","article-title":"The role of SOX family members in solid tumours and metastasis","volume":"67","author":"Grimm","year":"2020","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189186_bb0245","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1172\/JCI78815","article-title":"SOX9 drives WNT pathway activation in prostate cancer","volume":"126","author":"Ma","year":"2016","journal-title":"J. Clin. Invest."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189186_bb0250","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1210\/me.2014-1078","article-title":"Crosstalk between nuclear MET and SOX9\/\u03b2-catenin correlates with castration-resistant prostate cancer","volume":"28","author":"Xie","year":"2014","journal-title":"Mol. Endocrinol."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189186_bb0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20092066","article-title":"Interplay between SOX9, Wnt\/\u03b2-catenin and androgen receptor signaling in castration-resistant prostate cancer","volume":"20","author":"Khurana","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0260","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.3892\/ijo.2016.3641","article-title":"Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells","volume":"49","author":"Khurana","year":"2016","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0265","first-page":"825","article-title":"Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines","volume":"21","author":"Nakamura","year":"2002","journal-title":"Int. J. Oncol."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0270","doi-asserted-by":"crossref","first-page":"369","DOI":"10.4236\/jct.2014.54044","article-title":"Curcumin inhibits prostate cancer bone metastasis by up-regulating bone morphogenic protein-7 in vivo","volume":"5","author":"Dorai","year":"2014","journal-title":"J. Cancer Ther."},{"issue":"22","key":"10.1016\/j.bbcan.2024.189186_bb0275","doi-asserted-by":"crossref","first-page":"10423","DOI":"10.1158\/0008-5472.CAN-05-0824","article-title":"Identification of SFRP1 as a candidate mediator of stromal-to-epithelial signaling in prostate cancer","volume":"65","author":"Joesting","year":"2005","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0280","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118276","article-title":"Diagnostic value of SFRP1 as a favorable predictive and prognostic biomarker in patients with prostate cancer","volume":"10","author":"Zheng","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2024.189186_bb0285","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s12935-020-01333-5","article-title":"SFRP1 increases TMPRSS2-ERG expression promoting neoplastic features in prostate cancer in vitro and in vivo","volume":"20","author":"Cruz-Hern\u00e1ndez","year":"2020","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.bbcan.2024.189186_bb0290","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopha.2018.01.086","article-title":"miR-1301-3p promotes prostate cancer stem cell expansion by targeting SFRP1 and GSK3\u03b2","volume":"99","author":"Song","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189186_bb0295","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1038\/sj.bjc.6604976","article-title":"Secreted frizzled-related protein-1 is a negative regulator of androgen receptor activity in prostate cancer","volume":"100","author":"Kawano","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0300","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/bjc.2014.48","article-title":"Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells","volume":"110","author":"Hirata","year":"2014","journal-title":"Br. J. Cancer"},{"issue":"17","key":"10.1016\/j.bbcan.2024.189186_bb0305","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1073\/pnas.1304502110","article-title":"Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover","volume":"110","author":"Geng","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"13","key":"10.1016\/j.bbcan.2024.189186_bb0310","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1158\/0008-5472.CAN-12-3929","article-title":"The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer","volume":"73","author":"Tien","year":"2013","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.bbcan.2024.189186_bb0315","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1158\/0008-5472.CAN-14-0476","article-title":"Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer","volume":"74","author":"Geng","year":"2014","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0320","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/pros.24481","article-title":"Molecular features and race-associated outcomes of SPOP-mutant metastatic castration-resistant prostate cancer","volume":"83","author":"Stangl","year":"2023","journal-title":"Prostate"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0325","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1002\/pros.24269","article-title":"Clinical and genomic features of SPOP-mutant prostate cancer","volume":"82","author":"Nakazawa","year":"2022","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.bbcan.2024.189186_bb0330","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41588-018-0078-z","article-title":"The long tail of oncogenic drivers in prostate cancer","volume":"50","author":"Armenia","year":"2018","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0335","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174357","article-title":"LZTS2 and PTEN collaboratively regulate \u00df-catenin in prostatic tumorigenesis","volume":"12","author":"Yu","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0340","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1158\/0008-5472.CAN-19-1684","article-title":"Activation of \u03b2-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer","volume":"80","author":"Patel","year":"2020","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189186_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21124507","article-title":"The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling","volume":"21","author":"Shorning","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11\u221212","key":"10.1016\/j.bbcan.2024.189186_bb0350","first-page":"368","article-title":"Active \u03b2-catenin is regulated by the PTEN\/PI3 kinase pathway: a role for protein phosphatase PP2A","volume":"7","author":"Persad","year":"2016","journal-title":"Genes Cancer"},{"issue":"12","key":"10.1016\/j.bbcan.2024.189186_bb0355","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-17-3107","article-title":"Deptor is a novel target of Wnt\/\u03b2-catenin\/c-Myc and contributes to colorectal cancer cell growth","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res."},{"issue":"13","key":"10.1016\/j.bbcan.2024.189186_bb0360","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1073\/pnas.121173298","article-title":"Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor","volume":"98","author":"Lin","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"8","key":"10.1016\/j.bbcan.2024.189186_bb0365","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1158\/1541-7786.MCR-16-0480","article-title":"Glutamine transporters are targets of multiple oncogenic signaling pathways in prostate cancer","volume":"15","author":"White","year":"2017","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0370","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/pros.20050","article-title":"Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades","volume":"60","author":"Weichert","year":"2004","journal-title":"Prostate"},{"issue":"24","key":"10.1016\/j.bbcan.2024.189186_bb0375","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/onc.2012.309","article-title":"Plk1 is upregulated in androgen-insensitive prostate cancer cells and its inhibition leads to necroptosis","volume":"32","author":"Deeraksa","year":"2013","journal-title":"Oncogene"},{"issue":"22","key":"10.1016\/j.bbcan.2024.189186_bb0380","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.1158\/0008-5472.CAN-14-1916","article-title":"Plk1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer","volume":"74","author":"Zhang","year":"2014","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0385","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/0008-5472.CAN-22-1533","article-title":"Plk1 inhibitors and abiraterone synergistically disrupt mitosis and kill cancer cells of disparate origin independently of androgen receptor signaling","volume":"83","author":"Patterson","year":"2023","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.bbcan.2024.189186_bb0390","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1128\/MCB.00825-15","article-title":"Cotargeting polo-like kinase 1 and the Wnt\/\u03b2-catenin signaling pathway in castration-resistant prostate cancer","volume":"35","author":"Li","year":"2015","journal-title":"Mol. Cell. Biol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/genes10020134","article-title":"KDM4B: A nail for every hammer?","volume":"10","author":"Wilson","year":"2019","journal-title":"Genes (Basel)"},{"issue":"8","key":"10.1016\/j.bbcan.2024.189186_bb0400","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1093\/nar\/gkt106","article-title":"The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover","volume":"41","author":"Coffey","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0405","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/jcp.29117","article-title":"Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy","volume":"235","author":"Sha","year":"2020","journal-title":"J. Cell. Physiol."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0410","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.canlet.2012.11.051","article-title":"HoxB3 promotes prostate cancer cell progression by transactivating CDCA3","volume":"330","author":"Chen","year":"2013","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0415","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41419-023-05742-y","article-title":"HOXB3 drives WNT-activation associated progression in castration-resistant prostate cancer","volume":"14","author":"Zhu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"7559","key":"10.1016\/j.bbcan.2024.189186_bb0420","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.bbcan.2024.189186_bb0425","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1158\/1078-0432.CCR-22-3350","article-title":"Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN\/p53-deficient prostate cancer","volume":"29","author":"Chaudagar","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"23","key":"10.1016\/j.bbcan.2024.189186_bb0430","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1158\/1078-0432.CCR-23-1441","article-title":"Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN\/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis","volume":"29","author":"Chaudagar","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189186_bb0435","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/bjc.2017.451","article-title":"WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages","volume":"118","author":"Lee","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0440","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1042\/EBC20220016","article-title":"WNT signaling and cancer stemness","volume":"66","author":"Katoh","year":"2022","journal-title":"Essays Biochem."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0445","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0450","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/cr.2009.43","article-title":"WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics","volume":"19","author":"Bisson","year":"2009","journal-title":"Cell Res."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0455","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1158\/1078-0432.CCR-15-0190","article-title":"Targeting cancer stem cells in castration-resistant prostate cancer","volume":"22","author":"Yun","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189186_bb0460","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/0008-5472.CAN-14-1924","article-title":"Aldehyde dehydrogenase is regulated by \u03b2-catenin\/TCF and promotes radioresistance in prostate cancer progenitor cells","volume":"75","author":"Cojoc","year":"2015","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0465","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1159\/000369749","article-title":"Regulation of autophagy of prostate cancer cells by \u03b2-catenin signaling","volume":"35","author":"Lin","year":"2015","journal-title":"Cell. Physiol. Biochem."},{"issue":"7","key":"10.1016\/j.bbcan.2024.189186_bb0470","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/pros.23776","article-title":"Dihydrotestosterone inhibits arylsulfatase B and Dickkopf Wnt signaling pathway inhibitor (DKK)-3 leading to enhanced Wnt signaling in prostate epithelium in response to stromal Wnt3A","volume":"79","author":"Bhattacharyya","year":"2019","journal-title":"Prostate"},{"issue":"19","key":"10.1016\/j.bbcan.2024.189186_bb0475","doi-asserted-by":"crossref","first-page":"6068","DOI":"10.1158\/0008-5472.CAN-13-0882","article-title":"ERG is a critical regulator of Wnt\/LEF1 signaling in prostate cancer","volume":"73","author":"Wu","year":"2013","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101970","article-title":"WLS-Wnt signaling promotes neuroendocrine prostate cancer","volume":"24","author":"Bland","year":"2021","journal-title":"iScience"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0485","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","article-title":"Phase 1 study of single-agent WNT974, a first-in-class porcupine inhibitor, in patients with advanced solid tumours","volume":"125","author":"Rodon","year":"2021","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0490","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1158\/0008-5472.CAN-12-2258","article-title":"Pharmacological inhibition of the Wnt acyltransferase PORCN prevents growth of WNT-driven mammary cancer","volume":"73","author":"Proffitt","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189186_bb0495","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2019.02.009","article-title":"Modulating Wnt signaling at the root: porcupine and Wnt acylation","volume":"198","author":"Torres","year":"2019","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0500","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10060165","article-title":"CRISPR-mediated reactivation of DKK3 expression attenuates TGF-\u03b2 signaling in prostate cancer","volume":"10","author":"Kardooni","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.bbcan.2024.189186_bb0505","doi-asserted-by":"crossref","first-page":"9617","DOI":"10.1158\/0008-5472.CAN-05-0829","article-title":"Adenovirus-mediated overexpression of REIC\/Dkk-3 selectively induces apoptosis in human prostate cancer cells through activation of c-Jun-NH2-kinase","volume":"65","author":"Abarzua","year":"2005","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189186_bb0510","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.cgt.7701071","article-title":"Adenovirus-mediated REIC\/Dkk-3 gene transfer inhibits tumor growth and metastasis in an orthotopic prostate cancer model","volume":"14","author":"Edamura","year":"2007","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.bbcan.2024.189186_bb0515","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/CMO.S23252","article-title":"Ad-REIC gene therapy: promising results in a patient with metastatic CRPC following chemotherapy","volume":"9","author":"Kumon","year":"2015","journal-title":"Clin. Med. Insights Oncol."},{"issue":"21","key":"10.1016\/j.bbcan.2024.189186_bb0520","doi-asserted-by":"crossref","first-page":"14236","DOI":"10.1074\/jbc.M808002200","article-title":"Overexpression of REIC\/Dkk-3 in normal fibroblasts suppresses tumor growth via induction of interleukin-7","volume":"284","author":"Sakaguchi","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"39","key":"10.1016\/j.bbcan.2024.189186_bb0525","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1038\/s41388-018-0294-0","article-title":"Protective effect of stromal Dickkopf-3 in prostate cancer: opposing roles for TGFBI and ECM-1","volume":"37","author":"Al Shareef","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0530","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/carcin\/bgv153","article-title":"Dickkopf-3 regulates prostate epithelial cell acinar morphogenesis and prostate cancer cell invasion by limiting TGF-\u03b2-dependent activation of matrix metalloproteases","volume":"37","author":"Romero","year":"2016","journal-title":"Carcinogenesis"},{"issue":"10","key":"10.1016\/j.bbcan.2024.189186_bb0535","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0026539","article-title":"Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome","volume":"6","author":"Syed Khaja","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0540","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1002\/cam4.5","article-title":"Emphasizing the role of Wnt5a protein expression to predict favorable outcome after radical prostatectomy in patients with low-grade prostate cancer","volume":"1","author":"Khaja","year":"2012","journal-title":"Cancer Med."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189186_bb0545","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184418","article-title":"Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model","volume":"12","author":"Canesin","year":"2017","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bbcan.2024.189186_bb0550","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1158\/0008-5472.CAN-22-3003","article-title":"WNT5a signaling through ROR2 activates the hippo pathway to suppress YAP1 activity and tumor growth","volume":"83","author":"Wang","year":"2023","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189186_bb0555","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1158\/1535-7163.MCT-22-0216","article-title":"Bioengineered BERA-Wnt5a siRNA targeting Wnt5a\/FZD2 signaling suppresses advanced prostate cancer tumor growth and enhances enzalutamide treatment","volume":"21","author":"Ning","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"24","key":"10.1016\/j.bbcan.2024.189186_bb0560","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.21037\/atm-21-6191","article-title":"A comprehensive characterization of the transcriptome in enzalutamide resistance prostate cancer","volume":"9","author":"Wang","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"17","key":"10.1016\/j.bbcan.2024.189186_bb0565","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1158\/0008-5472.CAN-10-0244","article-title":"FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells","volume":"70","author":"Gupta","year":"2010","journal-title":"Cancer Res."},{"issue":"16","key":"10.1016\/j.bbcan.2024.189186_bb0570","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1002\/pros.23704","article-title":"Wnt receptor frizzled 8 is a target of ERG in prostate cancer","volume":"78","author":"Chakravarthi","year":"2018","journal-title":"Prostate"},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0575","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100747","article-title":"Wnt signaling drives prostate cancer bone metastatic tropism and invasion","volume":"13","author":"Wang","year":"2020","journal-title":"Transl. Oncol."},{"issue":"22","key":"10.1016\/j.bbcan.2024.189186_bb0580","doi-asserted-by":"crossref","first-page":"10627","DOI":"10.1111\/jcmm.17000","article-title":"Down-regulated LINC00115 inhibits prostate cancer cell proliferation and invasion via targeting miR-212-5p\/FZD5\/Wnt\/\u03b2-catenin axis","volume":"25","author":"Peng","year":"2021","journal-title":"J. Cell. Mol. Med."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0585","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bbrc.2015.12.054","article-title":"MicroRNA-613 represses prostate cancer cell proliferation and invasion through targeting Frizzled7","volume":"469","author":"Ren","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"18","key":"10.1016\/j.bbcan.2024.189186_bb0590","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1038\/s41388-022-02255-4","article-title":"GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling","volume":"41","author":"Wang","year":"2022","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0595","doi-asserted-by":"crossref","first-page":"8537","DOI":"10.1038\/s41598-018-26761-2","article-title":"Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics","volume":"8","author":"Han","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0600","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10549-020-05817-w","article-title":"Phase Ib clinical trial of the anti-frizzled antibody vantictumab (OMP-18R5) plus paclitaxel in patients with locally advanced or metastatic HER2-negative breast cancer","volume":"184","author":"Diamond","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189186_bb0605","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1080\/19420862.2018.1515565","article-title":"A synthetic anti-frizzled antibody engineered for broadened specificity exhibits enhanced anti-tumor properties","volume":"10","author":"Pavlovic","year":"2018","journal-title":"MAbs"},{"issue":"24","key":"10.1016\/j.bbcan.2024.189186_bb0610","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1158\/1078-0432.CCR-17-2157","article-title":"A first-in-human phase I study of the anticancer stem cell agent Ipafricept (OMP-54F28), a decoy receptor for Wnt ligands, in patients with advanced solid tumors","volume":"23","author":"Jimeno","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.bbcan.2024.189186_bb0615","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1158\/1078-0432.CCR-20-0489","article-title":"Phase Ib study of Wnt inhibitor Ipafricept with gemcitabine and nab-paclitaxel in patients with previously untreated stage IV pancreatic cancer","volume":"26","author":"Dotan","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0620","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ygyno.2019.04.001","article-title":"A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer","volume":"154","author":"Moore","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0625","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1042\/BCJ20180385","article-title":"Niclosamide-induced Wnt signaling inhibition in colorectal cancer is mediated by autophagy","volume":"476","author":"Wang","year":"2019","journal-title":"Biochem. J."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189186_bb0630","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0029290","article-title":"Niclosamide suppresses cancer cell growth by inducing Wnt co-receptor LRP6 degradation and inhibiting the Wnt\/\u03b2-catenin pathway","volume":"6","author":"Lu","year":"2011","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0635","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/s41598-021-85969-x","article-title":"Phase Ib trial of reformulated niclosamide with abiraterone\/prednisone in men with castration-resistant prostate cancer","volume":"11","author":"Parikh","year":"2021","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0640","doi-asserted-by":"crossref","first-page":"235","DOI":"10.4196\/kjpp.2015.19.3.235","article-title":"Androgen receptor-dependent expression of low-density lipoprotein receptor-related protein 6 is necessary for prostate cancer cell proliferation","volume":"19","author":"Park","year":"2015","journal-title":"Korean J. Physiol. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0645","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2023.113857","article-title":"LRP5 competes for SPOP binding to enhance tumorigenesis mediated by Daxx and PD-L1 in prostate cancer","volume":"434","author":"Gan","year":"2024","journal-title":"Exp. Cell Res."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0650","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.cellsig.2014.02.018","article-title":"Rottlerin induces Wnt co-receptor LRP6 degradation and suppresses both Wnt\/\u03b2-catenin and mTORC1 signaling in prostate and breast cancer cells","volume":"26","author":"Lu","year":"2014","journal-title":"Cell. Signal."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189186_bb0655","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/jcb.24850","article-title":"Salinomycin suppresses LRP6 expression and inhibits both Wnt\/\u03b2-catenin and mTORC1 signaling in breast and prostate cancer cells","volume":"115","author":"Lu","year":"2014","journal-title":"J. Cell. Biochem."},{"issue":"12","key":"10.1016\/j.bbcan.2024.189186_bb0660","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.cellsig.2012.07.009","article-title":"Silibinin inhibits Wnt\/\u03b2-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells","volume":"24","author":"Lu","year":"2012","journal-title":"Cell. Signal."},{"issue":"19","key":"10.1016\/j.bbcan.2024.189186_bb0665","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.febslet.2011.08.046","article-title":"Mesd is a general inhibitor of different Wnt ligands in Wnt\/LRP signaling and inhibits PC-3 tumor growth in vivo","volume":"585","author":"Lin","year":"2011","journal-title":"FEBS Lett."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189186_bb0670","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1158\/0008-5472.CAN-21-1807","article-title":"Autocrine canonical Wnt signaling primes noncanonical signaling through ROR1 in metastatic castration-resistant prostate cancer","volume":"82","author":"Ma","year":"2022","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0675","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.stem.2018.05.018","article-title":"Phase I trial: cirmtuzumab inhibits ROR1 signaling and stemness signatures in patients with chronic lymphocytic leukemia","volume":"22","author":"Choi","year":"2018","journal-title":"Cell Stem Cell"},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0680","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.37349\/etat.2023.00192","article-title":"Receptor tyrosine kinase-like orphan receptor 1 inhibitor strictinin exhibits anti-cancer properties against highly aggressive androgen-independent prostate cancer","volume":"4","author":"Sivaganesh","year":"2023","journal-title":"Explor. Target Antitumor. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0685","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13062-024-00469-y","article-title":"UBE2N promotes cell viability and glycolysis by promoting Axin1 ubiquitination in prostate cancer cells","volume":"19","author":"Yang","year":"2024","journal-title":"Biol. Direct"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0690","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1038\/s41598-019-41182-5","article-title":"The WNT\/\u03b2-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro","volume":"9","author":"Stakheev","year":"2019","journal-title":"Sci. Rep."},{"issue":"21","key":"10.1016\/j.bbcan.2024.189186_bb0695","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232112837","article-title":"Docetaxel resistance in castration-resistant prostate Cancer: transcriptomic determinants and the effect of inhibiting Wnt\/\u03b2-catenin signaling by XAV939","volume":"23","author":"Pudova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189186_bb0700","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/s41416-018-0110-1","article-title":"Endothelial Akt1 loss promotes prostate cancer metastasis via \u03b2-catenin-regulated tight-junction protein turnover","volume":"118","author":"Gao","year":"2018","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0705","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1042\/BJ20121140","article-title":"Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt\/PKB down-regulation and GSK3 activation","volume":"452","author":"Venerando","year":"2013","journal-title":"Biochem. J."},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0710","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1021\/acsomega.8b03205","article-title":"Mechanistic investigation of the androgen receptor DNA-binding domain inhibitor pyrvinium","volume":"4","author":"Pal","year":"2019","journal-title":"ACS Omega"},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0715","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1021\/cb400759d","article-title":"Ligand-independent and tissue-selective androgen receptor inhibition by pyrvinium","volume":"9","author":"Lim","year":"2014","journal-title":"ACS Chem. Biol."},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0720","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1038\/s41467-023-43676-3","article-title":"The ELAVL3\/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer","volume":"14","author":"Ji","year":"2023","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.bbcan.2024.189186_bb0725","first-page":"245","article-title":"Characterization of soy-based changes in Wnt-frizzled signaling in prostate cancer","volume":"7","author":"Liss","year":"2010","journal-title":"Cancer Genomics Proteomics"},{"issue":"2","key":"10.1016\/j.bbcan.2024.189186_bb0730","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jgr.2016.12.014","article-title":"Anticancer activity and potential mechanisms of 1C, a ginseng saponin derivative, on prostate cancer cells","volume":"42","author":"Wang","year":"2018","journal-title":"J. Ginseng Res."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189186_bb0735","doi-asserted-by":"crossref","DOI":"10.3390\/nu9090948","article-title":"Ho, chemopreventive potential of ethanolic extracts of luobuma leaves (Apocynum venetum L.) in androgen insensitive prostate cancer","volume":"9","author":"Huang","year":"2017","journal-title":"Nutrients"},{"key":"10.1016\/j.bbcan.2024.189186_bb0740","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41421-020-0171-1","article-title":"A PROTAC peptide induces durable \u03b2-catenin degradation and suppresses Wnt-dependent intestinal cancer","volume":"6","author":"Liao","year":"2020","journal-title":"Cell Discov."},{"issue":"17","key":"10.1016\/j.bbcan.2024.189186_bb0745","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202000208","article-title":"Aptamer\/peptide-functionalized genome-editing system for effective immune restoration through reversal of PD-L1-mediated cancer immunosuppression","volume":"32","author":"He","year":"2020","journal-title":"Adv. Mater. (Deerfield Beach, Fla.)"},{"issue":"1","key":"10.1016\/j.bbcan.2024.189186_bb0750","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1038\/s41467-023-40701-3","article-title":"One-step generation of tumor models by base editor multiplexing in adult stem cell-derived organoids","volume":"14","author":"Geurts","year":"2023","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbcan.2024.189186_bb0755","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.3892\/ol.2016.4161","article-title":"BCL9, a coactivator for Wnt\/\u03b2-catenin transcription, is targeted by miR-30c and is associated with prostate cancer progression","volume":"11","author":"Ling","year":"2016","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.bbcan.2024.189186_bb0760","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1158\/0008-5472.CAN-13-3311-T","article-title":"miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt\/\u03b2-catenin\/BCL9 pathway","volume":"74","author":"Zhao","year":"2014","journal-title":"Cancer Res."},{"issue":"17","key":"10.1016\/j.bbcan.2024.189186_bb0765","doi-asserted-by":"crossref","first-page":"eabm3108","DOI":"10.1126\/sciadv.abm3108","article-title":"A novel \u03b2-catenin\/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer","volume":"8","author":"Tanton","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.bbcan.2024.189186_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2023.129591","article-title":"Design, synthesis, and biological evaluation of novel 8-substituted quercetin derivatives targeting the \u03b2-catenin\/B-cell lymphoma 9 interaction","volume":"98","author":"Peng","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.bbcan.2024.189186_bb0775","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/cas.12995","article-title":"Logical design of an anti-cancer agent targeting the plant homeodomain in Pygopus2","volume":"107","author":"Ali","year":"2016","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0780","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1158\/0008-5472.CAN-15-1519","article-title":"A Small-molecule antagonist of the \u03b2-catenin\/TCF4 interaction blocks the self-renewal of cancer stem cells and suppresses tumorigenesis","volume":"76","author":"Fang","year":"2016","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.bbcan.2024.189186_bb0785","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1158\/0008-5472.CAN-14-2041","article-title":"Wnt\/\u03b2-catenin small-molecule inhibitor CWP232228 preferentially inhibits the growth of breast cancer stem-like cells","volume":"75","author":"Jang","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2024.189186_bb0790","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/1479-5876-11-280","article-title":"Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells","volume":"11","author":"Bilir","year":"2013","journal-title":"J. Transl. Med."},{"issue":"10","key":"10.1016\/j.bbcan.2024.189186_bb0795","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1002\/ijc.24810","article-title":"Small molecule antagonists of Tcf4\/beta-catenin complex inhibit the growth of HCC cells in vitro and in vivo","volume":"126","author":"Wei","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"11","key":"10.1016\/j.bbcan.2024.189186_bb0800","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/pros.22828","article-title":"Androgen receptor (AR) suppresses normal human prostate epithelial cell proliferation via AR\/\u03b2-catenin\/TCF-4 complex inhibition of c-MYC transcription","volume":"74","author":"Antony","year":"2014","journal-title":"Prostate"},{"issue":"9","key":"10.1016\/j.bbcan.2024.189186_bb0805","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1158\/1535-7163.MCT-11-0182","article-title":"Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines","volume":"10","author":"Santer","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bbcan.2024.189186_bb0810","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejmech.2018.01.087","article-title":"Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP\/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer","volume":"147","author":"Xiang","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"11","key":"10.1016\/j.bbcan.2024.189186_bb0815","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26113162","article-title":"Synthesis and biological evaluation of spirocyclic chromane derivatives as a potential treatment of prostate cancer","volume":"26","author":"Feng","year":"2021","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0820","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11670-012-0264-y","article-title":"Anacardic acid (6-pentadecylsalicylic acid) induces apoptosis of prostate cancer cells through inhibition of androgen receptor and activation of p53 signaling","volume":"24","author":"Tan","year":"2012","journal-title":"Chin. J. Cancer Res."},{"issue":"7674","key":"10.1016\/j.bbcan.2024.189186_bb0825","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0830","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.bbrc.2008.10.171","article-title":"Natural derivatives of curcumin attenuate the Wnt\/beta-catenin pathway through down-regulation of the transcriptional coactivator p300","volume":"377","author":"Ryu","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.bbcan.2024.189186_bb0835","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/pcan.2010.26","article-title":"Curcumin interrupts the interaction between the androgen receptor and Wnt\/\u03b2-catenin signaling pathway in LNCaP prostate cancer cells","volume":"13","author":"Choi","year":"2010","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"10.1016\/j.bbcan.2024.189186_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2024.122328","article-title":"Curcumin loaded \u03b2-cyclodextrin-magnetic graphene oxide nanoparticles decorated with folic acid receptors as a new theranostic agent to improve prostate cancer treatment","volume":"340","author":"Einafshar","year":"2024","journal-title":"Carbohydr. Polym."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24001173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X24001173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T08:50:12Z","timestamp":1733907012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X24001173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":168,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S0304419X24001173"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189186","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination therapies with Wnt signaling inhibition: A better choice for prostate cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2024.189186","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189186"}}